About
Antisense Oligonucleotides for Neuro Indications
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyBoston & New England
Team (10)
Anne Valat, PhD
Director of Research
Bolden Therapeutics
team_member
Ashley E. Webb, PhD
Scientific Founder, SAB Member
Bolden Therapeutics
founder
Charles Polsky, MD
Executive Chairman
Bolden Therapeutics
board_chair
Joel Richter, PhD
SAB Member
Bolden Therapeutics
team_member
Johnny Page, ScM
Co-Founder & CEO
Bolden Therapeutics
executivefounder
Justin R. Fallon, PhD
Scientific Founder, SAB Chair
Bolden Therapeutics
board_chairfounder
Clinical Trials (1)
View allTotal Trials
1
As Lead Sponsor
1
As Collaborator
0
Total Enrollment
220
By Phase
PHASE1/PHASE2: 1
By Status
RECRUITING: 1
Clinical Trials Pipeline1 trial
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Locations (1)
Headquarters
Providence, RI, United States
Map
Loading map...